		名 ~~~! ~~~
	HEALTH AND HUMAN SERVI DRUG ADMINISTRATION	CES
DISTRICT OFFICE ADDRESS AND PHONE NUMBER		DATE(5) OF INSPECTION
300 River Place, Suite 5900		05/25/10-06/16/10
Detroit, MI 48207		Contract A to the State of Sta
(313) 393-8100 Fax: (313) 393-8139		FEI NUMBER
Industry Information: www.fda.gov/oc/industry		1000306317
NAME AND TITLE OF INDIVIDUAL TO WHOM REPORT IS ISSUED		· · · · · · · · · · · · · · · · · · ·
	250426 26	
TO: Robert V. Markey, Chief Executive Officer, Biomedica		
FIRM NAME	STREET ADDRESS	
American National Red Cross, National Testing Lab	100 Eliot Street	
CITY, STATE AND ZIP CODE	TYPE OF ESTABLISHM	ENT INSPECTED
Detroit, MI 48201-2408	Blood Bank,	
THIS DOCUMENT LISTS OBSERVATIONS MADE BY THE FOA REPRESENTATIVE(S) DURING REPRESENT A FINAL AGENCY DETERMINATION REGARDING YOUR COMPLIANCE, IF YOU CORRECTIVE ACTION IN RESPONSE TO AN OBSERVATION, YOU MAY DISCUSS THE OBJ	I HAVE AN OBJECTION REGARDING AN ECTION OR ACTION WITH THE FDA REP	OBSERVATION, OR HAVE IMPLEMENTED, OR PLAN TO IMPLEMENT RESENTATIVE(S) DURING THE INSPECTION OR SUBMIT THIS
DURING AN INSPECTION OF YOUR FIRM WE OBSERVED:		
OBSERVATION 1 Annual competency reviews and/or quality assurance process not being correctly performed according to work instructions,		
Specifically,		
A.) Twenty-one of 31 employees performing addition of reag (b) (4) or the part prior to placement on the machine. Beginning in 2007, this st exception report E-0542911. Competency assessments perfor instruction to ensure appropriate rare reagent loading. No per the failure to correctly complete 1 or more required tasks) during	kage insert, both of which ep was incorrectly performed med during this time period sonnel were found to have i	have required assessors to use this work
B.) Employees of Detroit NTL completing the task of replace process correctly according to both the (b) (4) User's Manual. Both of these references require repla April 2008, this step was incorrectly performed for approxima period, all competency assessments completed for these person solution mixing and loading, including replacement of the cap reviews during this time. In 2009, Quality Process Reviews w (b) (4) purge solution to ensure the direction "If a new solution the Viral Processing Laboratory. Reviews indicated that this soperating (b) (4)	cement of the cap and stem ately 2 years according to examel required assessors to us assembly. No personnel which specifically included son, add new cap and stem as	and the assembly with a new assembly. Beginning in assembly make the coption report E-0796638. During this time se this work instruction to ensure correct purge were found to have failed the competency an assessment of the preparation and loading of assembly" was being followed were completed in
	3 (

SEE
REVERSE
OF THIS
FAGE
SIGNATURE

EMPLOYEE(S) NAME AND TITLE (Print or Type)
Barbara A. Rusin, Investigator
L'Oreal D. Fowlkes, Investigator
Sherri J. Blessman, Investigator

DATÉ ISSUED 06/16/10

図 いんせんかん VUI VUI EV IV 12.00 1 110 DEPARTMENT OF HEALTH AND HUMAN SERVICES FOOD AND DRUG ADMINISTRATION DISTRICT OFFICE ADDRESS AND PHONE NUMBER DATE(S) OF INSPECTION 300 River Place, Suite 5900 05/25/10-06/16/10 Detroit, MI 48207 FEI NUMBER (313) 393-8100 Fax: (313) 393-8139 1000306317 Industry Information: www.fda.gov/oc/industry NAME AND TITLE OF INDIVIDUAL TO WHOM REPORT IS ISSUED TO: Robert V. Markey, Chief Executive Officer, Biomedical Services FIRM NAME STREET ADDRESS American National Red Cross, National Testing Lab 100 Eliot Street CITY, STATE AND ZIP CODE TYPE OF ESTABLISHMENT INSPECTED Detroit, MI 48201-2408 Blood Bank, THIS DOCUMENT LISTS OBSERVATIONS MADE BY THE FDA REPRESENTATIVE(S) DURING THE INSPECTION OF YOUR FACILITY, THEY ARE INSPECTIONAL OBSERVATIONS; AND DO NOT REPRESENT A FINAL AGENCY DETERMINATION REGARDING YOUR COMPLIANCE. IF YOU HAVE AN OBJECTION REGARDING AN OBSERVATION, OR HAVE IMPLEMENTED, OR PLAN TO IMPLEMENT CORRECTIVE ACTION IN RESPONSE YO AN OBSERVATION, YOU MAY DISCUSS THE OBJECTION OR ACTION WITH THE FDA REPRESENTATIVE(S) DURING THE INSPECTION OR SUBMIT THIS INFORMATION TO FDA AT THE ADDRESS ABOVE. IF YOU HAVE ANY QUESTIONS, PLEASE CONTACT FDA AT THE PHONE NUMBER AND ADDRESS ABOVE. **OBSERVATION 2** Failure to adequately investigate and correct a problem. Specifically, on 02/05/10 review of proficiency testing attestation forms completed between 01/01/09 and 12/31/09 was performed by a quality control supervisor. This review indicated that of the 23 reviewed attestations, 2 were missing signatures for employees who performed proficiency tests. This problem was logged as Level 1 exception E-0744002. A communication was sent to "all Detroit NTL supervisors of the VTL, APL and NAT, QC supervisor/lead and production managers/BOT stating the importance of attestation form signatures and supervisors roles in verifying that signatures are captured at the time of testing." During the current inspection, it was discovered that there were an additional 13 employees who completed proficiency tests between the dates of 01/01/09 and 12/31/09, but did not sign attestations. During that time period a total of 93 employees completed proficiency testing, Exceptions E-0816805 and E-0818851 were logged on 06/03/10 and 06/08/10, respectively, in regards to these findings. Both exceptions are related to issue I-0020416-FC which is currently open to document investigation of root cause(s) and development and implementation of corrective action plan(s). These exceptions also document the added findings during the inspection that between the dates of 11/01/08 and 12/31/08, 7 employees completed proficiency tests, with 1 not having signed the correct attestation; and since 01/01/10, a total of 38 employees have completed proficiency tests, with 4 not having signed the appropriate attestation.

SEE REVERSE

OF THIS

PAGE

geal No. Someres

Barbara A. Rusin, Investigator

L'Oreal D. Fowlkes, Investigator

EMPLOYEE(S) NAME AND TITLE (Print or Type)

DATE ISSUED

06/16/10